Results of a Time and Motion Survey Regarding Subcutaneous versus Intravenous Administration of Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma

References

• Ramsenthaler C, Kane P, Gao W, et al. Prevalence of symptoms in patients with multiple myeloma: a systematic review and meta-analysis. Eur J Haematol. 2016;97(5):416–429. doi:10.1111/ejh.12790
   PubMed Web of Science ®Google Scholar
• Baz R, Lin HM, Hui AM, et al. Development of a conceptual model to illustrate the impact of multiple myeloma and its treatment on health-related quality of life. Support Care Cancer. 2015;23(9):2789–2797. doi:10.1007/s00520-015-2644-6
   PubMed Web of Science ®Google Scholar
• Parsons JA, Greenspan NR, Baker NA, McKillop C, Hicks LK, Chan O. Treatment preferences of patients with relapsed and refractory multiple myeloma: a qualitative study. BMC Cancer. 2019;19(1):264. doi:10.1186/s12885-019-5467-x
   PubMed Web of Science ®Google Scholar
• Seitzler S, Finley-Oliver E, Simonelli C, Baz R. Quality of life in multiple myeloma: considerations and recommendations. Expert Rev Hematol. 2019;12(6):419–424. doi:10.1080/17474086.2019.1613886
   PubMed Web of Science ®Google Scholar
• Szabo K, Bodoki L, Nagy-Vincze M, et al. Effect of genetic and laboratory findings on clinical course of antisynthetase syndrome in a Hungarian Cohort. Biomed Res Int. 2018;2018:6416378. doi:10.1155/2018/6416378
   Web of Science ®Google Scholar
• Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111(5):2516–2520. doi:10.1182/blood-2007-10-116129
   PubMed Web of Science ®Google Scholar
• Barbee MS, Harvey RD, Lonial S, et al. Subcutaneous versus intravenous bortezomib: efficiency practice variables and patient preferences. Ann Pharmacother. 2013;47(9):1136–1142. doi:10.1177/1060028013503122
   PubMed Web of Science ®Google Scholar
• Krejcik J, Casneuf T, Nijhof IS, et al. Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood. 2016;128(3):384–394. doi:10.1182/blood-2015-12-687749
   PubMed Web of Science ®Google Scholar
• DARZALEX® (daratumumab) injection, for intravenous use [prescribing information]. Horsham, PA: Janssen Biotech, Inc; 2020.
   Google Scholar
• Darzalex (daratumumab) [summary of product characteristics]. Leiden, The Netherlands: Janssen Biologics BV; 2020.
   Google Scholar
• Pivot X, Gligorov J, Muller V, et al. Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study. Lancet Oncol. 2013;14(10):962–970. doi:10.1016/S1470-2045(13)70383-8
   PubMed Web of Science ®Google Scholar
• Lugtenburg P, Avivi I, Berenschot H, et al. Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study. Haematologica. 2017;102(11):1913–1922. doi:10.3324/haematol.2017.173583
   PubMed Web of Science ®Google Scholar
• Rummel M, Kaiser U, Balser C, et al. Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial. Lancet Oncol. 2016;17(1):57–66. doi:10.1016/S1470-2045(15)00447-7
   PubMed Web of Science ®Google Scholar
• Nooka AK, Gleason C, Sargeant MO, et al. Managing infusion reactions to new monoclonal antibodies in multiple myeloma: daratumumab and elotuzumab. J Oncol Pract. 2018;14(7):414–422. doi:10.1200/JOP.18.00143
   PubMed Web of Science ®Google Scholar
• San-Miguel J, Usmani SZ, Mateos MV, et al. Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: part 2 of the open-label, multicenter, dose-escalation phase 1b study (PAVO). Haematologica; 2020. doi:10.3324/haematol.2019.243790
   PubMed Web of Science ®Google Scholar
• Clemens PL, Yan X, Lokhorst HM, et al. Pharmacokinetics of daratumumab following intravenous infusion in relapsed or refractory multiple myeloma after prior proteasome inhibitor and immunomodulatory drug treatment. Clin Pharmacokinet. 2017;56(8):915–924. doi:10.1007/s40262-016-0477-1
   PubMed Web of Science ®Google Scholar
• Usmani SZ, Nahi H, Mateos MV, et al. Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma. Blood. 2019;134(8):668–677. doi:10.1182/blood.2019000667
   PubMed Web of Science ®Google Scholar
• Mateos MV, Nahi H, Legiec W, et al. Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial. Lancet Haematol. 2020;7(5):e370–e380. doi:10.1016/S2352-3026(20)30070-3
   PubMed Web of Science ®Google Scholar
• DARZALEX FASPROTM (daratumumab and hyaluronidase-fihj) injection, for subcutaneous use [prescribing information]. Horsham, PA: Janssen Biotech, Inc; 2020.
   Google Scholar
• Blimark C, Holmberg E, Mellqvist UH, et al. Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Haematologica. 2015;100(1):107–113. doi:10.3324/haematol.2014.107714
   PubMed Web of Science ®Google Scholar
• Valkovic T, Gacic V, Ivandic J, et al. Infections in hospitalised patients with multiple myeloma: main characteristics and risk factors. Turk J Haematol. 2015;32(3):234–242. doi:10.4274/tjh.2013.0173
   Web of Science ®Google Scholar
• Tai E, Guy GP, Dunbar A, Richardson LC. Cost of cancer-related neutropenia or fever hospitalizations, United States, 2012. J Oncol Pract. 2017;13(6):e552–e561. doi:10.1200/JOP.2016.019588
   PubMed Web of Science ®Google Scholar
• Lazaro Cebas A, Cortijo Cascajares S, Pablos Bravo S, et al. Subcutaneous versus intravenous administration of trastuzumab: preference of HER2+ breast cancer patients and financial impact of its use. J BUON. 2017;22(2):334–339.
   PubMed Web of Science ®Google Scholar
• Fisher MD, Wallick CJ, Miller PJ, et al. Impacts of time spent on rituximab infusion on patient satisfaction, stress, employment, and caregiver burden. Value Health. 2018;21:S36. doi:10.1016/j.jval.2018.04.303
   Web of Science ®Google Scholar
• Barbosa CD, Balp MM, Kulich K, Germain N, Rofail D. A literature review to explore the link between treatment satisfaction and adherence, compliance, and persistence. Patient Prefer Adherence. 2012;6:39–48. doi:10.2147/PPA.S24752
   PubMed Web of Science ®Google Scholar
• Price D, Harrow B, Small M, Pike J, Higgins V. Establishing the relationship of inhaler satisfaction, treatment adherence, and patient outcomes: a prospective, real-world, cross-sectional survey of US adult asthma patients and physicians. World Allergy Organ J. 2015;8(1):26. doi:10.1186/s40413-015-0075-y
   PubMed Web of Science ®Google Scholar
• Sweileh WM, Ihbesheh MS, Jarar IS, et al. Self-reported medication adherence and treatment satisfaction in patients with epilepsy. Epilepsy Behav. 2011;21(3):301–305. doi:10.1016/j.yebeh.2011.04.011
   PubMed Web of Science ®Google Scholar
• Small M, Anderson P, Vickers A, Kay S, Fermer S. Importance of inhaler-device satisfaction in asthma treatment: real-world observations of physician-observed compliance and clinical/patient-reported outcomes. Adv Ther. 2011;28(3):202–212. doi:10.1007/s12325-010-0108-4
   PubMed Web of Science ®Google Scholar
• Kurtin S, Lilleby K, Spong J. Caregivers of multiple myeloma survivors. Clin J Oncol Nurs. 2013;17(s6):Suppl:25–32. doi:10.1188/13.CJON.S2.25-32
   Web of Science ®Google Scholar
• Armoogum J, Richardson A, Armes J. A survey of the supportive care needs of informal caregivers of adult bone marrow transplant patients. Support Care Cancer. 2013;21(4):977–986. doi:10.1007/s00520-012-1615-4
   Web of Science ®Google Scholar
• Molassiotis A, Wilson B, Blair S, Howe T, Cavet J. Living with multiple myeloma: experiences of patients and their informal caregivers. Support Care Cancer. 2011;19(1):101–111. doi:10.1007/s00520-009-0793-1
   PubMed Web of Science ®Google Scholar
• Stenberg U, Ruland CM, Miaskowski C. Review of the literature on the effects of caring for a patient with cancer. Psychooncology. 2010;19(10):1013–1025. doi:10.1002/pon.1670
   PubMed Web of Science ®Google Scholar
• Erikson C, Salsberg E, Forte G, Bruinooge S, Goldstein M. Future supply and demand for oncologists: challenges to assuring access to oncology services. J Oncol Pract. 2007;3(2):79–86. doi:10.1200/JOP.0723601
   PubMedGoogle Scholar
• Sharma D, Wallace N, Levinsohn EA, et al. Trends and factors affecting the US adult hematology workforce: a mixed methods study. Blood Adv. 2019;3(22):3550–3561. doi:10.1182/bloodadvances.2019000307
   PubMed Web of Science ®Google Scholar
• Rosenman R, Tennekoon V, Hill LG. Measuring bias in self-reported data. Int J Behav Healthc Res. 2011;2(4):320–332. doi:10.1504/IJBHR.2011.043414
   PubMedGoogle Scholar
• De Cock E, Kritikou P, Sandoval M, et al. Time savings with rituximab subcutaneous injection versus rituximab intravenous infusion: a time and motion study in eight countries. PLoS One. 2016;11(6):e0157957. doi:10.1371/journal.pone.0157957
   PubMed Web of Science ®Google Scholar
• Barr H, Dempsey J, Waller A, et al. Ninety-minute daratumumab infusion is safe in multiple myeloma. Leukemia. 2018;32(11):2495–2518. doi:10.1038/s41375-018-0120-2
   PubMed Web of Science ®Google Scholar
• De Cock E, Pivot X, Hauser N, et al. A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2-positive early breast cancer. Cancer Med. 2016;5(3):389–397. doi:10.1002/cam4.573
   PubMed Web of Science ®Google Scholar